Kinases play a critical role in many cellular signaling pathways and are dysregulated in a number 17 of diseases, such as cancer, diabetes, and neurodegeneration. Since the FDA approval of imatinib in 2001, 18 therapeutics targeting kinases now account for roughly 50% of current cancer drug discovery efforts. The 19 ability to explore human kinase biochemistry, biophysics, and structural biology in the laboratory is essential 20 to making rapid progress in understanding kinase regulation, designing selective inhibitors, and studying 21 the emergence of drug resistance. While insect and mammalian expression systems are frequently used 22 for the expression of human kinases, bacterial expression systems are superior in terms of simplicity and 23 cost-effectiveness but have historically struggled with human kinase expression. Following the discovery that 24 phosphatase coexpression could produce high yields of Src and Abl kinase domains in bacterial expression 25 systems, we have generated a library of 52 His-tagged human kinase domain constructs that express above 26 2 g/mL culture in a simple automated bacterial expression system utilizing phosphatase coexpression 27 (YopH for Tyr kinases, Lambda for Ser/Thr kinases). Here, we report a structural bioinformatics approach to 28 identify kinase domain constructs previously expressed in bacteria likely to express well in a simple high-29 throughput protocol, experiments demonstrating our simple construct selection strategy selects constructs 30 with good expression yields in a test of 84 potential kinase domain boundaries for Abl, and yields from a high-31 throughput expression screen of 96 human kinase constructs. Using a fluorescence-based thermostability 32 assay and a fluorescent ATP-competitive inhibitor, we show that the highest-expressing kinases are folded 33 and have well-formed ATP binding sites. We also demonstrate how the resulting expressing constructs 34 can be used for the biophysical and biochemical study of clinical mutations by engineering a panel of 48 35 Src mutations and 46 Abl mutations via single-primer mutagenesis and screening the resulting library for 36 expression yields. The wild-type kinase construct library is available publicly via Addgene, and should prove 37 to be of high utility for experiments focused on drug discovery and the emergence of drug resistance. 38 39 1 of 20
Introduction structural data can produce constructs with useful expression levels, enabling simple identification of 89 construct domain boundaries. We then completed an automated expression screen in Rosetta2 cells of 90 96 different kinases and found that 52 human kinase domains express with yields greater than 2 g/mL 91 culture. To investigate whether these kinases are properly folded and useful for biophysical experiments, we 92 performed a fluorescence-based thermostability assay on the 14 highest expressing kinases in our panel 93 and a single-well high-throughput fluorescence-based binding affinity measurement on 39 kinases. These 94 experiments demonstrated that omany of the expressed kinases were folded, with well formed ATP binding 95 sites capable of binding a small molecule kinase inhibitor. To demonstrate the utility of these constructs for 96 probing the effect of clinical mutations on kinase structure and ligand binding, we subsequently screened 48 97 Src and 46 Abl mutations, finding that many clinically-derived mutant kinase domains can be expressed with 98 useful yields in this uniform automated expression and purification protocol. 99 All source code, data, and wild-type kinase plasmids associated with this project are freely available 106 To understand how alternative choices of expression construct boundaries can modulate bacterial expres-107 sion of a human kinase domain, we carried out an expression screen of 84 unique construct boundaries 108 encompassing the kinase domain of the tyrosine protein kinase ABL1. Three constructs known to express in bacteria were chosen from the literature and used as controls, 110 spanning Uniprot residues 229-500 (PDBID: 3CS9) 23 , 229-512 (PDBID: 2G2H) 24 and 229-515 (PDBID: 2E2B) 25 . 111 81 constructs were generated combinatorially by selecting nine different N-terminal boundaries spanning 112 residues 228-243 and nine different C-terminal boundaries spanning residues 490-515, chosen to be near 113 the start and end points for the control constructs ( Figure 1A) . Each of the three control constructs included 114 six replicates to provide an estimate of the typical standard error in expression readout for the experimental 115 constructs, which was found to be between 0.42-1.5 g/mL ( Figure 1A , green constructs). 116 Briefly, the impact of construct boundary choice on Abl kinase domain expression was tested as follows 117 (see Methods for full details). His10-TEV N-terminally tagged wild-type Abl constructs 2 were coexpressed 118 with YopH phosphatase in a 96-well format with control replicates distributed randomly throughout the 119 plate. His-tagged protein constructs were recovered via a single nickel affinity chromatography step, and 120 construct yields were quantified using microfluidic capillary electrophoresis following thermal denaturation. 121 Expression yields are summarized in Figure 1A , and a synthetic gel image from the constructs with detectable 122 expression is shown in Figure 2 . Abl construct bands are present at sizes between 29 and 35 kDa (due to 123 the variation in construct boundaries), and YopH phosphatase (which is not His-tagged but has substantial 124 affinity for the nickel beads) is present in all samples at its expected size of 50 kDa. Strikingly, despite the 125 fact that N-terminal and C-terminal construct boundaries only varied over 15-25 residues, only a small 126 number of constructs produced detectable expression ( Figure 1B ). As highlighted in Figure 1C (left), the 127 best N-terminal boundaries (residues 228, 229, 230) are located on a disordered strand distant from any 128 secondary structure; N-terminal boundaries closer to the beta sheet of the N-lobe gave poor or no detectable 129 expression ( Figure 1B ). 130 The best C-terminal construct boundaries (residues 511 and 512) occur in an -helix ( Figure 1C , right). Of 131 note, this -helix is not resolved in PDBID:2E2B 25 , suggesting this structural element may only be weakly 132 thermodynamically stable in the absence of additional domains. In previous work, this -helix was shown to 133 undergo a dramatic conformational change which introduces a kink at residue 516, splitting the -helix into 134 two 26 . This suggests a high potential for flexibility in this region. 135 Two of the control constructs (which differ in construct boundary by only one or two residues) were in the 136 top six expressing constructs ( Figure 1A) Instead of eluting with imidazole, purified kinase was cleaved off nickel beads by the addition of 10% 167 TEV protease to minimize phosphatase contamination in the resulting eluate, allowing us to assess whether 168 resulting yields would be sufficient (and sufficiently free of phosphatase) to permit activity assays. While the 169 initial panel of 96 kinases was well-distributed among kinase families ( Figure 3B ), the most highly expressing 170 kinases (yield of more than 12 g kinase/mL culture) were not evenly distributed ( Figure 3D ). While many of 171 the kinases chosen from the CMGC and CK1 families expressed well in our panel, nearly all of the kinases 172 from the CAMK and AGC family express below 12 g kinase/mL ( Figure 3D ). 52 kinases demonstrated a 173 useful level of soluble protein expression, here defined as greater than 2 g/mL, naïvely expected to scale 174 up to better than 2 mg/L culture (Table 1) . Some kinases (shaded green in Table 1 ) demonstrated very high 175 levels of expression, while others (shaded orange in Table 1 ) would likely benefit from further rounds of 176 construct boundary optimization or solubility tags to boost soluble expression. The 17 most highly expressing 177 kinases showed relatively high purity after elution, though we note that eluting via TEV site cleavage results 178 in a quantity of TEV protease in the eluate ( Figure 3C ), but does not cause the elution of the His-tagged 179 phosphatases which would hinder the ability to perform kinase activity assays. Further optimization of 180 elution conditions may be required for optimizing kinase recovery via TEV cleavage 28-30 . 181 Constructs with expression yields above 2 g/mL have been made available via Addgene: A fluorescence-based thermostability assay was performed on the 14 kinases shown to express above a minimum 0.24 mg/mL concentration after elution. SYPRO Orange fluorescence (solid blue line) was measured at 580 nm (half bandwidth 20 nm) after excitation at 465 nm (half bandwith 25 nm) as as the temperature was ramped from (x-axis) in Nickel Buffer A (25 mM HEPES pH 7.5, 5% glycerol, 400 mM NaCl, 20 mM imidazole, 1 mM BME). The temperature was held at 25 • C for 15 sec before ramping up to 95 • C with a ramp rate of 0.06 • C/s. The unfolding temperature (black dashed line and insert) was determined from the maxima of the normalized first derivative of fluorescence (red dashed line). Fluorescence emission at 580 nm is shown on the left y-axis. To control for signals resulting from TEV protease contamination present at 0.01-0.03 mg/mL, TTK, a kinase with no detectable expression in our panel as determined via Caliper GX II quantitation was in included (panel 15).
Construct boundary choice impacts Abl kinase domain expression
had sufficient yields to prepare 100 L of 0.5 M kinase assay solutions, and were assessed for binding to Figure 6A) , with wild-type sequences included as controls. Mutations were introduced using site-directed 248 mutagenesis and assayed for expression yields ( Figure 6B ). Those with yields above 2 g kinase/mL culture 249 are listed in Table 2 . 250 High-expressing mutants appear to be distributed relatively uniformly throughout the kinase domain 251 ( Figure 6A ). While the vast majority of the Src mutants expressed at a usable level, many of the Abl mutants 252 expressed below the 2 g/mL threshold. This can primarily be attributed to the low level of expression for 253 wild-type Abl construct (Table 1 ). In instances where kinase activity is not required, yield could be increased 254 via the introduction of inactivating mutations 21 or further tailoring of expression and purification protocols. format-faq-v1.html), "All residues in the crystal or in solution, including residues not present in the model (i.e., 280 disordered, lacking electron density, cloning artifacts, HIS tags) are included in the SEQRES records." However, 281 we found that these records are very often misannotated, instead representing only the crystallographically 282 resolved residues. Since expression levels can be greatly affected by insertions or deletions of only one or a 283 few residues at either terminus 47 , it is important to know the full experimental sequence. To measure the 284 authenticity of a given SEQRES record, we developed a simple metric by hypothesizing that most crystal 285 structures would likely have at least one or more unresolved residues at one or both termini and that 286 the presence of an expression tag, which is typically not crystallographically resolved, would indicate an 287 authentic SEQRES record. To achieve this, unresolved residues were first defined by comparing the SEQRES 288 sequence to the resolved sequence, using the SIFTS service to determine which residues were not present 289 in the canonical isoform sequence 48 . Regular expression pattern matching was used to detect common 290 expression tags at the N-or C-termini. Sequences with a detected expression tag were given a score of 2, 291 while those with any unresolved sequence at the termini were given a score of 1, and the remainder were 292 given a score of 0. This data was stored to allow for subsequent selection of PDB constructs based on likely 293 authenticity in later steps. The number of residues extraneous to the target kinase domain, and the number 294 of residue conflicts with the UniProt canonical isoform within that domain span were also stored for each 295 PDB sequence. Automation of the construct selection process 326 While much of this process was performed programmatically, many steps required manual supervision and 327 intervention to correct for exceptional cases. While these exceptions were encoded programmatically as 328 overrides to ensure the scheme could be reproduced from existing data, we hope to eventually develop a 329 fully automated software package for the selection of expression construct sequences for a given protein 330 family, but this was not possible within the scope of this work. Fluorescence-based thermostability assay 375 To assess whether the highly-expressed wild-type kinase constructs are folded, a thermofluor thermostability 376 assay 31-33 was performed for kinase constructs that have a minimum of 0.24 mg/mL protein concentration 377 in the eluate. After diluting 9 L of eluate by 1 L dye, the effective assay concentration is 0.216 mg/mL 378 minimum in 10 L assay volume. Previous optimization efforts in the lab determined that 0.20 mg/mL was 379 the lower limit of well-defined T detection. This minimum concentration also ensured that the kinase was 380 present at roughly an order of magnitude concentration higher than contaminating TEV protease. to where the construct is truncated with respect to the secondary structure of the protein, as disrupting 464 secondary structure could cause the protein to improperly fold, leading to low soluble protein yield even 465 when total expression is high. Of note, the highest expressing C-terminal boundaries for Abl were residues 466 511 and 512. These residues fall in the regulatory alpha helix I 26 . This helix has been shown to undergo a 467 dramatic conformational change upon binding to the myristoylated N-terminal cap, which introduces a sharp 468 "kink" in residues 516-519. These residues may lead to higher levels of soluble expression by truncating 469 an secondary structural element that is unusually flexible. Indeed, this helix is not resolved in some X-ray 470 structures (PDBID:2E2B) 25 , further suggesting that this helix is less thermodynamically stable than expected. 471 Control replicates of three constructs indicate good repeatability of expression yields in the high-throughput 472 format. This screen suggests that optimization of construct boundaries could potentially further greatly 473 increase yields of poorly expressing kinase domains. Codon optimization for bacterial expression could 474 also increase expression for kinase domains with low yield due to codon bias 49 , as could coexpression with 475 chaperones 50 . 476 For those kinases that did express, a fluorescence-based thermostability assay indicated that many of the 477 highest-expressing kinases are well folded. An ATP-competitive inhibitor binding fluorescent assay provides 478 qualitative evidence that the 39 kinases that had sufficiently high expression levels to be assayed have a 479 well-formed ATP-binding site capable of binding bosutinib, a small molecule ATP-competitive kinase inhibitor. 480 Taken together, these two experiments demonstrate that our expression protocol produces folded kinases 481 with utility for biophysical experiments and drug design. 482 The tolerance of these bacterial constructs to many engineered clinical missense mutations suggests 483 a promising route to the high-throughput biophysical characterization of the effect of clinical mutants on 484 anticancer therapeutics. Mutations that did not express well may destabilize the protein, or may increase the 485 specific activity of the kinase. A higher specific activity would require more phosphatase activity, wasting ATP 486 to prevent high levels of phosphorylation that have been hypothesized to cause difficulty expressing kinases 487 without a coexpressed phosphatase in bacteria 21 . Mutations that are destabilizing may show improved 488 expression if coexpressed with more elaborate chaperones such as GroEL and Trigger factor 50 . Mutations 489 that increase the specific activity of the kinase might also express better when combined with an inactivating 490 mutation. 491 High-throughput automated kinase expression could be combined with enzymatic or biophysical tech-492 niques for characterizing the potency of a variety of clinical kinase inhibitors to assess which mutations 493 confer resistance or sensitivity. While the process of engineering, expressing, purifying, and assaying mu-494 tants currently takes approximately two weeks, it is possible that new techniques for cell-free bacterial 495 expression 51,52 may reduce this time to a matter of days or hours in a manner that might be compatible with 496 clinical time frames to impact therapeutic decision-making. 497 We hope that other laboratories find these resources useful in their own work. 
